CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 123 filers reported holding CYMABAY THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is 0.29 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,692 | -42.8% | 113,450 | -58.0% | 0.00% | -25.0% |
| Q2 2023 | $2,957 | -29.6% | 270,020 | -43.9% | 0.00% | -33.3% |
| Q1 2023 | $4,199 | +32.4% | 481,500 | -4.8% | 0.01% | +50.0% |
| Q4 2022 | $3,172 | -99.8% | 505,900 | +3.1% | 0.00% | +100.0% |
| Q3 2022 | $1,718,000 | +13.2% | 490,800 | -4.6% | 0.00% | 0.0% |
| Q2 2022 | $1,518,000 | +6.2% | 514,620 | +12.0% | 0.00% | 0.0% |
| Q1 2022 | $1,429,000 | +96.0% | 459,535 | +113.1% | 0.00% | +100.0% |
| Q4 2021 | $729,000 | -61.0% | 215,620 | -57.9% | 0.00% | -50.0% |
| Q3 2021 | $1,871,000 | -46.1% | 512,591 | -35.6% | 0.00% | -50.0% |
| Q2 2021 | $3,472,000 | -14.1% | 796,220 | -10.6% | 0.00% | -20.0% |
| Q1 2021 | $4,041,000 | +71.8% | 890,163 | +117.3% | 0.01% | +66.7% |
| Q4 2020 | $2,352,000 | +104.3% | 409,720 | +157.8% | 0.00% | +200.0% |
| Q3 2020 | $1,151,000 | +272.5% | 158,920 | +79.5% | 0.00% | – |
| Q2 2020 | $309,000 | -62.9% | 88,520 | -79.2% | 0.00% | -100.0% |
| Q4 2019 | $833,000 | +308.3% | 424,840 | +964.2% | 0.00% | – |
| Q3 2019 | $204,000 | -88.3% | 39,920 | -70.3% | 0.00% | -100.0% |
| Q2 2018 | $1,747,000 | 0.0% | 134,500 | 0.0% | 0.00% | -50.0% |
| Q1 2018 | $1,747,000 | -2.2% | 134,500 | -30.7% | 0.00% | 0.0% |
| Q4 2017 | $1,786,000 | -61.1% | 194,100 | -66.0% | 0.00% | -60.0% |
| Q3 2017 | $4,596,000 | +154.6% | 570,200 | +81.9% | 0.01% | +150.0% |
| Q2 2017 | $1,805,000 | +81.0% | 313,392 | +35.1% | 0.00% | +100.0% |
| Q1 2017 | $997,000 | +391.1% | 231,949 | +97.6% | 0.00% | – |
| Q4 2016 | $203,000 | -13.2% | 117,400 | -2.8% | 0.00% | – |
| Q3 2016 | $234,000 | +4.9% | 120,800 | -5.8% | 0.00% | – |
| Q2 2016 | $223,000 | +48.7% | 128,300 | +15.6% | 0.00% | – |
| Q1 2016 | $150,000 | +45.6% | 111,000 | +82.3% | 0.00% | – |
| Q4 2015 | $103,000 | – | 60,900 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lynx1 Capital Management LP | 1,653,495 | $10,367,414 | 8.97% |
| Versant Venture Management, LLC | 543,753 | $3,409,330 | 7.06% |
| TCG Crossover Management, LLC | 5,905,400 | $37,026,858 | 6.54% |
| COMMODORE CAPITAL LP | 5,738,500 | $35,980 | 5.42% |
| Foresite Capital Management IV, LLC | 1,787,094 | $11,205,079 | 4.79% |
| Saturn V Capital Management LP | 1,611,778 | $5,718,432 | 4.74% |
| ACUTA CAPITAL PARTNERS, LLC | 1,015,000 | $6,364,050 | 3.92% |
| Altium Capital Management LP | 1,025,000 | $6,426,750 | 3.27% |
| Affinity Asset Advisors, LLC | 1,143,531 | $7,169,939 | 2.81% |
| GREAT POINT PARTNERS LLC | 1,550,000 | $9,718,500 | 1.90% |